SUPERNUS PHARMACEUTICALS, INC. 8K

Supernus Pharmaceuticals and Indivior agreed to an all-stock merger of equals to form a larger CNS-focused biopharma company expected to close in Q4 2026.

Supernus Pharmaceuticals, Inc. announced that it has entered into an agreement with Indivior to combine the two companies in an all-stock merger of equals, creating a leading U.S. biopharmaceutical company focused on central nervous system diseases, with four key commercial franchises (SUBLOCADE, Qelbree, Zurzuvae, and Onapgo/GOCOVRI), an expanded R&D pipeline in epilepsy, depression, and ADHD, and a stronger financial profile; the transaction, in which Jack (from Supernus) will serve as Chief Executive Officer of the combined company, is expected to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals and other customary conditions.

Filing Facts

CIK

1356576

Ticker

SUPN

Form

8K

Source Type

fda

Accession

0001104659-26-089839

Alert Tier

8